322
Views
4
CrossRef citations to date
0
Altmetric
Review

Recent trends in neuropathic pain patents

Pages 539-546 | Received 05 Jul 2016, Accepted 13 Dec 2016, Published online: 28 Dec 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Daniela Salvemini & Kenneth A. Jacobson. (2017) Highly selective A3 adenosine receptor agonists relieve chronic neuropathic pain. Expert Opinion on Therapeutic Patents 27:8, pages 967-967.
Read now

Articles from other publishers (3)

Yan Zhang, Tingting Wang, Sanlan Wu, Li Tang, Jia Wang, Jinghan Yang, Shanglong Yao & Yan Zhang. (2023) Notch signaling pathway: a new target for neuropathic pain therapy. The Journal of Headache and Pain 24:1.
Crossref
Jing-Ai Wang, Shao-Ning Niu & Fang Luo. (2020) Pulsed radiofrequency alleviated neuropathic pain by down-regulating the expression of substance P in chronic constriction injury rat model. Chinese Medical Journal 133:2, pages 190-197.
Crossref
Irina Raicher, Patrick Raymond Nicolas Andre Ghislain Stump, Simone Bega Harnik, Rodrigo Alves de Oliveira, Rosemari Baccarelli, Lucia H.S.C. Marciano, Somei Ura, Marcos C.L. Virmond, Manoel Jacobsen Teixeira & Daniel Ciampi de Andrade. (2018) Neuropathic pain in leprosy: symptom profile characterization and comparison with neuropathic pain of other etiologies. PAIN Reports 3:2, pages e638.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.